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Our understanding of the pathogenesis of bladder cancer has improved considerably over the past decade. Translating these novel
pathobiological discoveries into therapies, prevention, or strategies to manage patients who are suspected to have or who have
been diagnosed with bladder cancer is the ultimate goal. In particular, the chemoprevention of bladder cancer development is
important, since urothelial cancer frequently recurs, even if the primary cancer is completely removed. The numerous alterations
of both oncogenes and tumor suppressor genes that have been implicated in bladder carcinogenesis represent novel targets for
therapy and prevention. In addition, knowledge about these genetic alterations will help provide a better understanding of the
biological signiﬁcance of preneoplastic lesions of bladder cancer. Animal models for investigating bladder cancer development and
prevention can also be developed based on these alterations. This paper summarizes the results of recent preclinical and clinical
chemoprevention studies and discusses screening for bladder cancer.
1.Introduction
There has recently been an increasing incidence of and
signiﬁcant mortality rates attributed to bladder cancer.
Fortunately, our understanding of the pathobiology of
this malignancy has improved considerably over the past
decade. Translating these novel pathobiological discoveries
into therapies or strategies to manage patients who are
suspected to have or who have been previously diagnosed
with bladder cancer is the ultimate goal. Of the three
main histological variants of epithelial malignancies arising
from the urothelium of the urinary bladder, transitional
cell carcinoma (TCC, Figure 1) is the most prevalent in
Japan, North America, and other developed countries, while
squamous cell carcinoma (Figure 2) and adenocarcinoma
(Figure 2) are diagnosed less frequently.
In this paper, the reported alterations of both oncogenes
and tumor suppressor genes in bladder cancer will be
outlined and described in the context of possible novel
therapies targeting these alterations. Several investigators
have hypothesized that certain chromosomal abnormali-
ties and mutations play deﬁnite roles in bladder cancer
development, while other alterations correlate with tumor
progression. This paper will also describe the molecular
basis of known malignant phenotypes. These ﬁndings will
provide insight into the biological and clinical signiﬁcance of
variouspreneoplasticlesions.Inaddition,wewillsummarize
the reports in the areas of chemoprevention and screening
for bladder cancer. Emphasis will be placed on how the
novel biological ﬁndings have impacted the development of
tests to screen for bladder cancer and on the pathogenesis
and chemoprevention of bladder cancer. Finally, animal
models are useful for investigating cancer development and
prevention, so we will discuss the use of animal models
for studying bladder carcinogenesis and bladder cancer
prevention and treatment.2 Journal of Oncology
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Figure 1: Natural history of bladder cancer (transitional cell carcinoma). Tis, transitional cell carcinoma in situ; and TCC, transitional cell
carcinoma.
2. Epidemiology of Bladder Cancer
An estimated 386.300 new cases and 150.200 deaths from
bladder cancer were diagnosed worldwide in 2008 [1]. The
majority of bladder cancer occurs in males, and there is a
14-fold variation in incidence internationally. The highest
incidence rates are found in the countries of Europe, North
America, and Northern Africa. Egyptian males have the
highest mortality rate (16.3 per 100.000), which is twice
as high as the highest rates in Europe (8.3 in Spain and
8.0 in Poland) and more than 4 times higher than that in
the United States (3.7) [2]. The countries of Melanesia and
Middle Africa have the lowest reported rates. Smoking and
occupational exposures are the major risk factors in West-
ern countries, whereas chronic infection with Schistosoma
haematobium in developing countries, particularly in Africa
and the Middle East, accounts for about 50% of the total
burden [3]. The majority of bladder cancers associated with
schistosomiasis are histologically squamous cell carcinoma,
while those associated with smoking are TCC [4].
3. Histopathology andNaturalHistoryof
Bladder Cancer
TCC can be classiﬁed into two groups with distinct behav-
ioral and molecular proﬁles: low-grade cancers (always
papillary and usually superﬁcial) and high-grade cancers
(either papillary or nonpapillary, and often invasive) [5–9].
Superﬁcial bladder cancers, such as stages Ta (superﬁcial),
Tis (in situ, Figure 1), and T1 (early invasive) account for
75% to 85% of neoplasms at clinical presentation, while the
remaining 15% to 25% are invasive (T2, T3, and T4) or
have metastasized at the time of diagnosis [10]. More than
70% of all patients treated for superﬁcial bladder cancer will
subsequently develop one or more recurrent tumors, and
about one-third of these patients will progress to cancer that
invades the surrounding muscle [11].
Several diﬀerent preneoplastic lesions for bladder can-
cer have been postulated. Certain hyperplastic changes or
evertedpapillomas(Figure 1)areconsideredtobesigniﬁcant
preexisting conditions (i.e., precursors) for the develop-
ment of overt papillary transitional cell carcinomas of low
grade. The other precursor lesions described within the
current nomenclature are related to the ﬂat Tis pathway
of tumorigenesis, including the changes known as intra-
urothelial neoplasms [12]. This latter group includes simple
hyperplasia, atypical urothelial hyperplasia, and dysplasia
(Figure 1) or marked atypia. Some authors have used the
t e r mT i sg r a d e s1 ,2 ,a n d3f o rm i l d ,m o d e r a t e ,a n ds e v e r e
dysplasia, respectively [13]. Several studies have revealed
the importance of diagnosing concomitant dysplasia, asJournal of Oncology 3
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Figure 2: Three main histological types of bladder cancer and their urinary cytology. TCC, transitional cell carcinoma; SCC, squamous cell
carcinoma; and ADC, adenocarcinoma.
it increases the risk of tumor progression for patients
aﬀected with superﬁcial bladder cancers [14, 15]. Finally,
squamous metaplasia followed by dysplastic changes is
generally accepted as being a premalignant lesion associated
with squamous cell carcinoma in bilharzial-related bladder
cancer (BBC). Regardless of the terminology, it is becoming
increasingly evident that the morphological changes and the
clinical manifestations of bladder cancer are preceded by
molecular and biochemical alterations.
The identiﬁcation of the multiple and complex chromo-
somal alterations in bladder TCC has led to the development
of the “clonal” theory of bladder cancer pathogenesis,
whichpostulatesthatmultifocalandrecurrenttumorsevolve
from a single transformed cell, from which all progenies
derive several identical genetic mutations [16]. The more
traditional “ﬁeld cancerization” theory assumes an overall
change in the urothelium, with many transformed cells
evolving independently into tumors, and therefore being4 Journal of Oncology
genetically unrelated [17]. The evidence for both theories is
compelling [18]. In reality, these theories are equally valid
and both processes can occur simultaneously in the same
patient [19].
In rats, urothelial carcinogenesis involves a sequence of
morphologic changes beginning as simple hyperplasia. It
then progresses to nodular and papillary hyperplasia. These
progresstopapillomasandcaneventuallyprogresstohigher-
grade, noninvasive carcinomas and ultimately to invasive
neoplasms (Figure 1)[ 20]. Many exophytic tumors induced
inratsarepolypoid,oftenpedunculatedandwithaninverted
papillary growth pattern [20]. Nodular hyperplasia, in mice,
is considerably more common than papillary proliferation,
and nodular hyperplasia frequently occurs with a complete
absence of papillary hyperplasia [21]. Therefore, the rat
model more strongly resembles papillary neoplasms, while
the mouse model resembles ﬂat urothelial lesions, both of
which have been identiﬁed in humans [22].
4. Risk Factors for Bladder Cancer
Aside from age, gender, and race, exposure to numerous
environmental agents and chemicals has been closely cor-
related with the risk of developing bladder cancer. Most
environmental bladder carcinogens are aromatic amines. A
Chinese herbal mixture containing Stephania tetrandra and
Magnolia oﬃcinalisthatwasimportedintoBelgiumasapop-
ular weight-reduction aid primarily used by women became
responsible for an epidemic of interstitial nephropathy,
presumably from contamination with Aristolochia fangchi,
which had been substituted for S. tetrandra [23]. Subse-
quently, patients with Chinese herb nephropathy have been
reported to be at much higher risk for developing urothelial
carcinoma, primarily of the upper urinary tract, but also of
the bladder [24]. A major mechanism causing this condition
appears to be the development of aristolochic acid-related
DNA adducts in the urothelium of both the upper urinary
tract and bladder. Public health measures for restricting
the distribution of these herbs are now in place in many
countries [25].
4.1. Occupational Exposure. The aniline dyes used to col-
or fabrics are urothelial carcinogens [1]. Other chemi-
cals that have been shown to be carcinogens for blad-
der cancer include 2-naphthylamine, 4-aminobiphenyl, 4-
nitrobiphenyl, 4-4-diaminobiphenyl (benzidine), and 2-
amino-1-naphthol [26]; combustion gases and soot from
coal; possibly chlorinated aliphatic hydrocarbons [26]; cer-
t a i na l d e h y d e ss u c ha sa c r o l e i nu s e di nc h e m i c a ld y e sa n d
in the rubber and textile industries [5]. Other potential
sources of carcinogenic compounds are dietary nitrites and
nitrates that are acted upon by intestinal bacterial ﬂora [27,
28] and contaminants of ingested herbal remedies such as
aristolochic acid [24]. Occupations reported to be associated
withanincreasedriskofbladdercancerincludeautoworkers,
painters, truck drivers, drill press operators, leather workers,
metal workers, and machinery operators, as well as those
occupations that involve organic chemicals, such as dry
cleaners, paper manufacturing, rope and twine makers, den-
tal technicians, barbers or beauticians, physicians, workers in
apparel manufacturing, and plumbers [29, 30].
4.2. Cigarette Smoking. Active cigarette smokers have a two-
to fourfold higher incidence of bladder cancer than do
people who have never smoked [31]. The speciﬁc chemical
carcinogen responsible for bladder cancer in cigarette smoke
hasnotbeenidentiﬁed.Nitrosamines,2-naphthylamine,and
4-aminobiphenyl are known to be present, and increased
urinarytryptophanmetaboliteshavealsobeendemonstrated
in cigarette smokers [32]. Two-thirds of bladder cancer cases
may be related to cigarette smoking and the risk, in both
sexes, correlates well with the number of cigarettes smoked,
the duration of smoking, and the degree of smoke inhalation
[33]. Smoking cessation signiﬁcantly reduces the bladder
cancer risk, however, even after 20–25 years, it never reaches
the baseline risk level of nonsmokers. Regardless of these
factors, from a clinical standpoint, it is important to realize
that not only does smoking increase the risk for developing
bladder cancer, but also that failure to quit smoking once a
diagnosis is made predicts a worse outcome, even in those
initially diagnosed with noninvasive cancers [34]. Other
formsoftobaccouseareassociatedwithonlyaslightlyhigher
risk for bladder cancer than the general population [31].
4.3. Infection. Urinary tract infection and chronic irritation
are associated with an increased risk of squamous cell
carcinoma of the bladder [35]. Two to 10% of paraplegics
with long-term indwelling catheters develop bladder cancer,
80% of which are squamous cell carcinomas. Managing
thesepatientswithoutchronicindwellingcathetersdecreased
the incidence of bladder cancer and the preponderance of
squamous cell carcinomas [36]. Unfortunately, despite these
favorable trends, well over half of these patients have invasive
cancers at diagnosis, a ﬁgure that is more than double
that found in the general population without spinal cord
injuries [37]. Despite this high risk, periodic screening via
cystoscopy and/or cytology (Figure 2) for patients with long-
termindwellingcatheters(intheabsenceofgrosshematuria)
isnotstronglysupported[38].Ontheotherhand,thisclearly
is a prime population for secondary preventive eﬀorts.
Bladder infection by Schistosoma haematobium,e s p e -
cially in endemic areas like Egypt, appears to be causally
related to the development of both squamous cell carcinoma
and less frequently, transitional cell carcinomas. The mech-
anisms of carcinogenesis are not yet understood but may
involve the formation of nitrite and N-nitroso compounds
in the bladder [39], presumably from parasitic (or microbial,
transmitted withtheparasite) metabolism of normalurinary
constituents [40].
The role of exposure to the human papillomavirus
(HPV) in bladder cancer has been evaluated by several
groups,withwidelydivergentﬁndings.Previousreportshave
indicated that as few as 2% [41] to as high as 35% of
humanbladdercancersarecontaminatedbyHPVDNA[42].
Griﬃths and Mellon [43] concluded that this virus was more
likely to play a role in transitional cell tumorigenesis inJournal of Oncology 5
immunocompromised hosts, rather than in cancers arising
in immunologically competent individuals. The role of other
viralagentsintheetiologyoftransitionalcellcancerhasbeen
investigated but not yet fully elucidated [44].
4.4. Radiation and Other Therapies. Female patients treated
with radiotherapy for carcinoma of the uterine cervix or
ovary have a twofold to fourfold increased risk of developing
bladder cancer compared with women only undergoing
surgery[45].Theincidencerisesfurtherifchemotherapywas
also administered (with or without cyclophosphamide) or
even if chemotherapy was used alone. The risks in all groups
continued to rise for 10 years after treatment [45]. These
tumors are characteristically high grade and locally advanced
at the time of diagnosis [45]. There is growing evidence that
an increased risk also occurs in males treated by external
beam irradiation for prostate cancer [46].
Similarly, a risk due to exposure to irradiation as seen
in the Chernobyl nuclear reactor accident is still present.
Patients undergoing evaluation for treatment due to urinary
retentionorchronicabacterialcystitisfromregionsthatwere
considered to be contaminated excreted far higher amounts
of 137Cs in their urine more than 15 years after the nuclear
accident than those residing in uncontaminated areas and
had signiﬁcantly more proliferative and dysplastic lesions on
mucosal biopsies than nonexposed individuals. In addition,
they had a 52% incidence of histological carcinoma in situ
and a 6.4% incidence of urothelial carcinomas compared to
0% in patients from uncontaminated areas [47].
Thepatientstreatedwithcyclophosphamideandexposed
to its urinary metabolite, acrolein [48], have up to a ninefold
increased risk of developing bladder cancer although the
speciﬁc relationship has not been formally demonstrated
in case-control epidemiological studies [49]. Most of these
high-grade and muscle-inﬁltrating tumors develop 6–13
yearsafterexposureandoccurinpatientsyoungerthanthose
with sporadic urothelial cancer and have an equal incidence
in both sexes [50]. Studies suggest that the uroprotectant,
mesna (2-mercaptoethanesulfonic acid), may reduce the risk
of bladder cancer [51]. Some authors suggest aggressive
therapy upon diagnosis (e.g., cystectomy), even when the
tumor is still noninvasive, because of the unusually high rate
of progression experienced by patients in whom cystectomy
is withheld [52].
Black-foot disease is endemic in South Taiwan, and it
is usually associated with vascular and cardiac disease and
with the development of numerous malignancies, including
transitional cell cancer of the bladder [53]. This condition
appearstoberelatedtoingestionoflargequantitiesofarsenic
in artesian well water. Similar endemic pockets of bladder
cancer are found in other regions with high arsenic con-
centrations in drinking water [54]. In a nested case-control
study, Liou et al. [53] demonstrated that speciﬁc cytogenetic
abnormalities, including chromosome-type breaks, gaps,
exchanges, and other aberrations, were more frequent in
peripheral blood cells and urothelial cells of exposed patients
who ultimately developed cancer over a 4-year period of
observationcomparedwithexposedindividualswhodidnot.
Regardless of the mechanism(s) of oncogenesis in this entity,
the incidence appears to be declining with eﬀective public
health measures focused on avoiding contaminated water.
Renal transplant recipients [55] and individuals hav-
ing a chronically low amount of ﬂuid ingestion [56]a r e
also at an increased risk for developing bladder cancer.
Transplant recipients, presumably because of prolonged
immunosuppression [54], are known to be at a higher risk
for developing numerous tumors. Similarly, if certain
chemicals are responsible for initiating mutational events,
prolongedexposuretohigherconcentrationsofthemislikely
to be more mutagenic/carcinogenic than exposure to lower
concentrations.
4.5. Hereditary Factors. Strong epidemiological evidence
does not exist for a hereditary cause of most cases of bladder
cancer. Perhaps the most compelling evidence in this regard
comes from the work of Klemeney and Schoenberg [57],
who studied the records of more than 12,000 relatives of 190
patients diagnosed with transitional cell cancer in Iceland
between 1983 and 1992. They found that while the risk of
developing transitional cell carcinoma was slightly elevated
in relatives (observed-to-expected odds ratio of 1.24, 95%
conﬁdence interval of 0.9 to 1.67), this ratio was greater
among second- and third- than ﬁrst-degree relatives. This
argues strongly against a straightforward genetic mechanism
being responsible. Familial clusters of bladder cancer have
been reported [57]. However, most of the authors did not
report whether this increased risk in the aﬀected families
was observed only in relatives who were smokers (or having
exposure to other putative carcinogens). This is important
because Kantor and associates [35] indicated that the
increasedfamilialriskwasprimarilyinrelativeswhosmoked.
The correlations between familial predisposition, possible
exposure, and some of the genotypic/phenotypic analyses
of enzymes responsible for the activation or inactivation of
putativebladdercancercarcinogensfoundincigarettesmoke
are therefore required to permit the identiﬁcation of at-risk
individuals who may be the best subjects for interventions
such as avoidance, prevention, and early detection strategies.
5. Screeningfor Bladder Cancer
As the natural history of bladder cancer is characterized by
multiple tumor recurrences and a risk of disease progression,
it is imperative that screening tests of high sensitivity and
speciﬁcity are available for evaluating patients at increased
risk of developing bladder cancer and for patients previously
treated for superﬁcial bladder cancer. Cystoscopy is the
gold standard against which all other tests are currently
compared. However, this test is both invasive and costly. As
a result, considerable emphasis has therefore been placed
on developing noninvasive tests for screening for bladder
cancer. Currently, the following noninvasive tests are either
being used in clinical practice or undergoing evaluation as
screening tests for bladder cancer: urine cytology (Figure 2),
bladder tumor antigen (BTA) (TRAK assay, Bard Diagnostic
Sciences, Redmond, Wash), nuclear matrix protein (NMP)6 Journal of Oncology
test (Matritech, Newton, Mass), ﬁbrin degradation product
(FDP) assay (Perlmmune, Rockville, Md), hyaluronic-acid
(HA-) hyaluronidase (HAase) urine test, and urine detection
of surviving [58]. With regard to gold standard for a non-
invasive screening test for bladder cancer, urine cytology is
inadequateduetoitslowsensitivityandsubjectivediagnostic
criteria. This has led to the development of the other
screeningtests,andeachofthesetestsshouldbecomparedto
the results of urine cytology to determine whether it might
oﬀer better diagnostic accuracy and sensitivity. The overall
sensitivity of urine cytology has been reported to be between
40 and 60%, with higher sensitivities being reported from
studies with a higher proportion of patients diagnosed with
high-grade tumors [12, 59, 60]. Although urine cytology has
a low sensitivity, it has consistently demonstrated excellent
speciﬁcity. We previously proposed the use of the number
of silver-stained nucleolar organizer regions of urothelial
cells in urine as a biomarker to detect urothelial malignancy
[61]. Determining the lactate dehydrogenase isoenzymes in
urinarycytologyhasalsoshowngooddiagnosticresults[62].
6. MolecularPathwayofBladderCarcinogenesis
6.1. Growth Signaling. Cancer cells have less dependence
on exogenous growth stimulation, generating many of their
growth signals in an autocrine fashion or by overexpressing
growth signal receptors to become hyperresponsive to nor-
m a lt i s s u el e v e l so fg r o w t hf a c t o r s[ 63]. Growth factor recep-
tors tend to have tyrosine kinase activity in their cytoplasmic
domains and are thus able to activate several intracellular
signaling pathways [63]. Downstream of the growth fac-
tors, the mitogen-activated protein kinase (MAPK) pathway
appears to be central, and mutations in its components
enable mitogenic signals to be propagated in the absence of
ongoing upstream stimulation [63].
The epidermal growth factor receptor (EGF-R) is a 175-
kDa transmembrane glycoprotein which is activated by the
binding of epidermal growth factor (EGF) and transforming
growth factor (TGF)-α [64] to its external domain, as
well as by betacellulin [64], epiregulin [65], amphiregulin
[64], and heparin-binding EGF-like factor [64], resulting in
proliferation, transformation, and division [66]. In bladder
TCCs, EGF-R expression is associated with a high tumor
grade [67] and stage [68], and rapid tumor proliferation
[69], and EGF-R mRNA can be used to detect circulating
neoplastic cells in patients’ blood [70]. TGF-α is considered
to be the more important ligand for EGF-R in bladder
tumors[71],anditsexpressioncorrelatesstronglywithdeath
from bladder cancer [72]. In vitro, EGF-R overexpression
increases bladder cancer cell motility [20], and EGF can
stimulate cancer cell growth and proliferation [73], as well
as invasion [74].
Hepatocyte growth factor (HGF) stimulates cell motility,
morphogenesis, and angiogenesis in vitro [75], and its recep-
tor (encoded by the c-met proto-oncogene) has tyrosine
kinase activity [76] .T h es e r u ma n dt i s s u el e v e l so fH G F
are signiﬁcantly higher in patients with muscle-invasive
tumors than in those with Ta/T1 bladder cancer, and both
the urinary and serum levels may be useful predictors of
the extent of disease and patient survival [77]. Although
HGF induces cell migration, invasion, and tumorigenicity in
malignant cell lines in vitro, it only stimulates proliferation
in nontumorigenic cell lines [78]. It has been proposed that
HGF is released in vivo by stromal cells and has diﬀerential
eﬀects on transformed and nontransformed urothelium
[76].
Fibroblast growth factors (FGFs) make up a family of 22
human polypeptide growth factors that have important and
diverse roles in embryonic development, which in adults can
contribute to the pathogenesis of cancer [79]. FGF-2 (basic
FGF) expression is elevated in high-stage bladder tumors
a n dc o r r e l a t e swi t he a r l yl o c a lr e c u r r e n c e[ 80]. FGF-1 (acidic
FGF) levels in the urine signiﬁcantly correlate with the stage
of disease [81], and in vitro, FGF-1 stimulation converts cells
from a noninvasive to a metastatic phenotype [82]. FGF-2
also increases the invasive potential of bladder cancer cell
lines [83]. FGF receptor-3 (FGF-R3) and TP53 mutations
have been recognized as the key genetic pathways in the
carcinogenesis of TCC; mutation of the former, being the
most frequently mutated oncogene, is strongly associated
with a low tumor grade, an early stage, and a low recurrence
rate, and mutation of the latter is associated with a higher
tumorgrade,moreadvancedstage,andmorefrequenttumor
recurrence [84].
Integrins are transmembrane receptors with diverse cell
adhesion and signaling functions, aﬀecting cell growth and
diﬀerentiation [85] and determining how cells interact
with the extracellular matrix [85]. The normal urothelium
expresses integrins α2, α3, β1, and β4, but not a1, a4, or α5
[86] .T h e r ei sal o s so fα2 expression as normal urothelial
tissue progresses to invasive TCC [86]. Integrin α6-β4i s
expressed by the basal layer of the normal urothelium and
low-stage TCCs, whereas invasive bladder cancers show loss
of α6-β4, and its loss can serve as a prognostic factor [87].
However, the speciﬁc roles of integrin signaling in bladder
carcinogenesis remain to be fully elucidated.
Many receptor tyrosine kinases and integrins activate a
sequential intracellular protein kinase cascade, termed the
MAPK module [39]. The role of the MAPK pathway in
thetransductionofsignalsfrommembrane-boundreceptors
(e.g., EGF-R and integrins) means that its speciﬁc therapeu-
tic manipulation is an attractive approach to cancer therapy,
and work in this area is already underway [88].
6.2. Antigrowth Signaling. In addition to growth stimu-
lation, antiproliferative signals also operate to maintain
quiescence and tissue homeostasis [63]. These antigrowth
signals are similarly received by cell-surface transmembrane
receptors linked to intracellular signaling pathways [63].
Most anti-proliferative signals use the retinoblastoma pro-
tein (pRB) and the related p107 and p130 proteins [89].
Cyclin-dependent kinases (CDKs) stimulate cell prolifer-
ation, while CDK inhibitors block cell proliferation [90]
and inhibit progression from the G2 to the M phase
of the cell cycle [91]. Many CDK inhibitors have been
identiﬁed: p2lWAF1/Cip1,p 2 7 Kip1,p 5 7 Kip2 (theCip/Kip family),Journal of Oncology 7
p15/INK4b, p16/INK4a, p18/INK4c, and p19/INK4d (the
INK4 family) [90].
pRBexpressionisfrequentlylostinbladdertumorsandis
signiﬁcantlycorrelatedwithhigh-gradecancer[92]andpoor
survival [93]. In addition, abnormal expression of both pRB
and p53 is signiﬁcantly associated with tumor proliferation,
muscle invasion, high grade, and higher recurrence and
progression rates than in patients with alterations in only
one of these proteins or no alterations in either [94]. The
p53 protein will be discussed in more detail later. Deletions
and mutations of the INK4 genes also occur frequently
in Ta/T1 bladder cancer, although only deletions aﬀecting
both p16 and p19, deregulating both the pRB and p53
pathways, correlate with a worse prognosis [95]. Reduced
expression of p27 is also signiﬁcantly associated with muscle
invasion [96]. Therefore, both the pRB and p53 pathways are
usually inactivated in bladder cancer that invades the muscle
layer [97], and such mutations and inactivations may act
synergistically to promote tumor progression [94].
The soluble signaling molecule TGFβ is a well-character-
ized antigrowth signal that induces the synthesis of p15 and
prevents cell-cycle progression [63]. Reduced expression of
the TGFβ1 gene in bladder tumors is signiﬁcantly associated
with high-grade [98] and advanced disease [99]. In addition,
loss of expression of the TGF-β receptors is signiﬁcantly
associated with a higher tumor grade and stage, the presence
of lymph node metastases, progression, and reduced survival
[96, 99].
6.3. Apoptosis Pathway. The prolonged survival of cells
harboring an abnormal genome and the expansion of the
resulting tumor rely not only on the rate of cell proliferation
but also on the rate of cell loss [63], and an acquired resis-
tance to apoptosis (programmed cell death) is a hallmark of
most, or possibly all, cancers [63]. The apoptotic pathway
comprises a complex arrangement of sensors, eﬀectors,
and regulators [63]. Kelly et al. [100] reviewed this area
speciﬁcally for bladder cancer. Survival factors include IGF-
1 and IGF-2 binding to their receptor IGF-1R [101]a n d
interleukin-3 binding to its receptor interleukin-3R [102].
Death signals include the Fas ligand, which binds to the
Fas receptor, tumor necrosis factor (TNF)-α, which binds
to TNF-R1, and the CD40 ligand binding to CD40 [103].
The apoptotic pathway is also activated in response to DNA
damage, signaling imbalances due to oncogene activation,
survivalfactorinsuﬃciency,orhypoxia[63].Thep53protein
initiates the transcription of the eﬀectors of apoptosis and
is considered to be the “guardian of the genome,” because it
can induce either apoptosis or DNA repair depending on the
extent of DNA damage and the eﬃcacy of repair [100].
After DNA damage, the increased levels of p53 protein
cause the transcriptional activation of p21WAF1, thus result-
ing in cell-cycle arrest [100]. Subsequently, proapoptotic
signals converge on the mitochondria, which respond by
releasing cytochrome C [104] to activate the ﬁnal eﬀectors
of apoptosis, the caspases [63, 100]. Regulation is achieved
by the bcl-2 family of proteins, which exert control on the
release of cytochrome C and the caspases [63, 100]. Bax,
Bak, Bid, and Bim are pro-apoptotic, whereas Bcl-2, Bcl-XL,
and Bcl-W are antiapoptotic member of this protein family
[63, 100]. These proteins dimerize and the resulting ratio of
inhibition to activation determines a cell’s susceptibility to
apoptosis [100]; a higher level of bax expression compared
to bcl-2 expression correlates with a better outcome for
patients with bladder cancer, and early relapses are more
common in patients whose tumors express more bcl-2 than
bax (both at the mRNA and protein levels) [105]. In a
multivariate analysis, bax immunostaining was found to be
a signiﬁcant predictor of better disease-free survival [106],
and bax and CD40 ligand are signiﬁcantly associated with
overall survival [107]. Bcl-2 expression has been linked to
poorer survival in patients with invasive bladder cancer
treated with synchronous chemoradiotherapy [108], and
overexpression of bcl-2 has been linked with poorer survival
in a group of patients with invasive bladder cancer treated
with neoadjuvant cisplatin [109].
Fas and CD40 are both members of the TNF-R family of
cell-surface proteins [110]. Fas mutations are seen in bladder
TCCs, leading to a potential loss of apoptotic function and
the generation of circulating soluble forms (sFas) of the
protein [110]. In vitro, the CD40/CD40 ligand interaction
induces apoptosis and growth arrest, as well as inducing
the release of proinﬂammatory cytokines [111], and in vivo,
TCCsthathaveinvadedthemuscletendtobeCD40negative,
in contrast to Ta/T1 TCCs which are mainly CD40 positive
[112].
These ﬁndings demonstrate the interplay among dif-
ferent elements of the apoptotic and cell cycle regulatory
pathwaysinbladdercancer,thushighlightingtheimportance
of p53, Fas, and CD40 as initiators of apoptosis, and while
also illustrating the regulation achieved by the balance of
pro- and anti-apoptotic proteins.
6.4. Replication Potential. The mechanisms discussed above
(growth signal autonomy, insensitivity to antigrowth signals,
and resistance to apoptosis) lead to the potential for limitless
replication [63]. However, these processes alone do not
ensure tumor growth; normal cells progress through a
limited number of replications before they stop dividing
and become senescent [63]. Telomeres are the “counting
devices” controlling the number of replications, and com-
prise hexanucleotide repeats (5-TTAGGG-3) that protect
the ends of chromosomes [63]. Eventually, after successive
replications, the protective telomeres are lost, resulting in
chromosomal disarray, crisis, and cell death [63]. However,
malignant cells are able to maintain telomere length above a
critical threshold to allow unlimited replication. To achieve
this, most malignant cells, including bladder cancer cells,
upregulate the expression of the enzyme telomerase which
adds the hexanucleotide repeats [113]. In bladder cancer,
telomerase activity is seen in all grades and stages of bladder
TCCs, but not in normal urothelium [114], and this suggests
that telomerase activation occurs as an early step in bladder
carcinogenesis [115].8 Journal of Oncology
6.5. Angiogenesis. Proliferative lesions increase their capa-
bility for growth and expansion by acquiring angiogenic
potential, and this neovascularization is essential for rapid
clonal expansion and the development of a macroscopic
tumor [63]. Angiogenesis is controlled by the balance of
pro- and antiangiogenic signals [63]. Proangiogenic signals
include vascular endothelial growth factor (VEGF), FGF1,
and FGF2 [116], while thrombospondin-1 is a typical
inhibitor of angiogenesis [117]. Thrombospondin-1 is also
positively regulated by the p53 protein, so loss of normal
p53 function, which occurs in most tumors, can release the
inhibition of angiogenesis [117].
Streeter and Harris [118] described the role of angiogen-
esis in bladder cancer in their paper. Bladder TCCs can stim-
ulate more angiogenesis than the normal urothelium, and
increased microvessel density is a signiﬁcant independent
prognostic indicator of recurrence and poor survival [119].
In muscle-invasive TCCs, microvessel counts signiﬁcantly
correlate with the presence of occult lymph-node metastases
[120]. In addition, high expression of bladder tumor VEGF
mRNA is signiﬁcantly associated with early recurrence,
progression to invasion, and high expression of mutantp53
protein [121]; high VEGF serum levels are signiﬁcantly
associated with high stage and grade, vascular invasion,
carcinoma in situ, metastases, and worse disease-free sur-
vival, [122]. Reduced thrombospondin-1 immunostaining is
signiﬁcantly associated with increased recurrence, decreased
survival and the expression of mutant p53 [119], and the in
vitro secretion of thrombospondin-1 by bladder cancer cells
is signiﬁcantly lower than that secreted by normal urothelial
cells [123].
The hypoxia-regulated protein, carbonic anhydrase (CA)
IX regulates the tissue pH and is a surrogate marker of
hypoxia in bladder cancer [124]. CA IX expression also
correlates with the VEGF expression in bladder cancer
[124].SigniﬁcantlymoreTa/T1thaninvasivebladdercancers
strongly express CA IX (82% versus 52%, resp., P = 0.03)
[125]. However, CA IX expression has no signiﬁcant corre-
lation with patient survival, suggesting that the dominant
role of CA IX occurs early in bladder transitional cell
carcinogenesis [124, 125].
Angiogenesis and its controlling factors thus have key
roles in bladder cancer initiation, progression, and invasion,
making this “hallmark” an attractive target for therapeutic
manipulation [126].
6.6. Invasion and Metastasis. Success in colonizing new sites
dependsonalloftheotherﬁveacquiredhallmarkcapabilities
discussed, but the initial ability to uncouple from the
primary tumor mass depends on the physical characteristics
of the cells [63]. The modulation of interactions with
neighboring cells and the extracellular matrix and the
production of proteases to degrade the extracellular matrix
and basement membrane are key processes in adopting an
invasive and metastatic phenotype [63].
Cadherins are the main mediators of cell-cell adhesion
in epithelial tissues, being major components of both the
adherens junction and desmosomes [127]. Adhesion is
achieved by homodimeric interactions between the extracel-
lular domains of classical cadherins (E-, P-, and N-cadherin)
on neighboring cells to form a “zipper”-like structure
[128]. Catenins (α-, β-, and γ-catenin and p120) anchor
the cadherins to the cell cytoskeleton [128]. E-cadherin
(epithelial-cadherin, L-CAM, uvomorulin, and cadherin-
1) is a tumor suppressor, and its expression is universally
downregulated during epithelial carcinogenesis. P-cadherin
(placental-cadherin,cadherin-3)behavesinasimilarfashion
toE-cadherininvitro[129].N-cadherin(neuronal-cadherin,
cadherin-2) has been shown to confer a more malignant
phenotype in some tumor model systems [130]. Therefore,
it was suggested that cadherin/catenin biology represents
a ubiquitous mechanism for epithelial cancer progression
[131].
In the urinary tract, E-cadherin and β-catenin are
expressed by membranes throughout the normal urothe-
lium. In bladder TCC, E-cadherin and β-catenin expression
decrease signiﬁcantly as the grade and stage increase, and
both have been shown to be independent prognostic factors
[132]. Mutations and hypermethylation of the E-cadherin
gene may play a role in the reduced expression seen in some
bladder tumors [133]. However, β-catenin-regulated gene
transcription does not appear to be important in bladder
transitionalcellcarcinogenesis[134].P-cadherinisexpressed
in the membrane only in the basal and parabasal layers of
normal urothelium [135]. However, P-cadherin expression
increases signiﬁcantly as the grade and stage progress, and
this is associated with a signiﬁcantly worse survival, with
P-cadherin being identiﬁed as an independent prognostic
factor [136, 137].
Desmosomes are also important for maintaining cell-
cell adhesion in epithelial tissues; desmosomal adhesion
inhibits invasive behavior, suggesting that they have a role
in suppressing tumor spread [138]. Invasive TCCs show
lowerdesmosomaldensitythannoninvasiveTCCs[139],and
modulation of desmosomal proteins appears to be an early
event in cell dissociation and the epithelial-mesenchymal
transition [140]. However, E-cadherin plays a stronger role
than the desmosomal cadherins in the control of invasion of
bladder cancer cells in vitro [141].
CD44 is a ubiquitous cell-surface adhesion molecule
involved in cell-cell and cell-matrix interactions, and at least
20 isoforms are known [142]. Quantitative and qualitative
c h a n g e si nC D 4 4v a r i a n t sh a v eb e e nr e p o r t e di nb l a d d e r
cancer [143], and some may have prognostic value [144].
Matrix-degrading proteases are associated with the cell-
surface and facilitate the invasion of cancer cells through
epithelialcelllayersandintonearbystromaandbloodvessels
[63]. The 24 human matrix metalloproteinases (MMPs)
are a family of proteolytic enzymes that degrade all of the
main components of the extracellular matrix and basement
membrane, and they are generally overexpressed in human
tumors [145]. In bladder cancer, both the expressions of
MMP-2 and MMP-9 expression increase signiﬁcantly as the
tumor grade and stage increase, with the MMP-2 expression
increasing signiﬁcantly as the grade and stage increase [146].
In vitro, MMP-1 production by bladder cancer cell lines can
be stimulated by EGF [146]; FGF-2 has also been shown toJournal of Oncology 9
have an important regulatory role [83]. There is currently
much interest in the clinical use of MMP inhibitors although
early trials have been disappointing [83].
6.7. Other Factors. Genomic instability allows clones of
premalignant cells to reach these six biological endpoints
and eventually develop into a tumor. Genomic maintenance
systems must be abrogated in order for all of these processes
to occur [63]. The roles of the p53 protein and apoptosis
are the most prominent of these maintenance systems [63].
The speciﬁc chromosomal alterations underlying bladder
carcinogenesis have been described [147]. In brief, deletions
of chromosome 9 occur in over half of bladder tumors of
all grades and stages (9p, 51%; 9q, 57%) [148]. A loss of
heterozygosity also occurs on 17p (32%), 11p (32%), 8p
(23%), 4p (22%), and 13q (15%), and loss of heterozygosity
of 5p, 8p, and 21q are signiﬁcantly associated with a worse
grade and stage [148]. Genomic copy number alterations
are also frequent in bladder TCC, with the most frequent
changes involving complete or partial loss of 4q (83%) and
gain of 20q (78%) [149]. Other frequent losses are of 18q
(65%), 8p (65%), 2q (61%), 6q (61%), 3p (56%), 13q
(56%), 4p (52%), 6p (52%), 10p (52%), 10q (52%), and 5p
(43%) [149]. Many of these loci are currently under further
investigation [6, 150, 151].
In addition to the mutations of genes, distinct structures
and functions of individual cells are achieved by diﬀerent
uses of the same genes and the same sequences with the
genome; epigenetic regulation is the mechanism by which
gene function is selectively activated or inactivated in cells
[152]. The concept of epigenetics has been described as
“heritable changes in gene expression that occur without a
change in DNA sequence” [152]. The regulation of DNA
methylation, histone acetylation, chromatin and chromo-
somes, transcriptional control, and genome dynamics forms
a closely interrelated epigenetic control system [152]. The
molecular components of this system have recently been
identiﬁed and include DNA methyltransferases, methyl-CpG
binding proteins, histone-modifying enzymes, chromatin
remodeling factors, transcription factors and their regulators
(e.g., myc protein/p62, max), and chromosomal proteins,
forming an integrated pathway [152]. Epigenetic changes in
bladder cancer have been reported, and the alterations are
attractive targets for cancer treatment with modulators that
demethylate DNA and inhibit histone deacetylases leading to
the reactivation of silenced genes [153]. Recently, Vallot et al.
[154] have identiﬁed a multiple regional epigenetic silencing
phenotype characterized by the concomitant epigenetic
silencing of several chromosomal regions, which, in bladder
cancer, is speciﬁcally associated with the carcinoma in situ
gene expression signature.
MicroRNAs (miRNA) are noncoding RNAs that post-
transcriptionally regulate gene expression. Their altered
e x p r e s s i o na n df u n ct i o nh a v eb e e no b s e rv e di nm o s tc a n c e r s ,
including bladder cancer [155]. More than 40miRNAs
have been implicated in urological cancer and many target
common carcinogenic pathways. In particular, avoidance of
apoptosis, cell proliferation, the epithelial-to-mesenchymal
transition, angiogenic signaling, and the generation of
androgen independence are targeted or facilitated by more
than one miRNA [156]. However, little work has so far been
done to evaluate the translational applications of this knowl-
edge to date. However, novel therapeutic strategies have
been developed and are under investigation to selectively
modulate miRNAs. Such work could therefore potentially
make it possible to perform personalized tumor therapy,
while also establishing eﬀective disease biomarkers.
7. Prevention of Bladder Cancer
For a variety of reasons, bladder cancer is a disease very well
suited to chemoprevention. The natural history of bladder
cancer is characterized by frequent recurrences, which
need to be minimized and carefully monitored. Second, in
addition to the genetic susceptibility, environmental factors
such as cigarette smoking and other carcinogens, which
come in contact with the urothelium, are involved in the
pathogenesis of bladder cancer. Therefore, the rationale
behind chemoprevention of bladder cancer lies in reduc-
ing and/or preventing the contact of these carcinogenic
chemicals with the urothelium. Potential chemopreventive
compounds administered systemically and excreted in the
urine should therefore have the favorable pharmacokinetic
property of remaining in close prolonged contact with the
urothelium. Diagnostic methods for bladder cancer, which
allow easy bladder access and tissue sampling, can be used to
evaluate the eﬃcacy of prevention strategies.
Three major types of prevention have been deﬁned:
primary prevention, which focuses on avoiding the devel-
opment of cancer in healthy subjects; secondary preven-
tion, which targets premalignant lesions with the intent of
avoiding their progression to cancer; tertiary prevention,
which focuses on preventing cancer progression in patients
diagnosed with early cancer and treated for the disease.
Primary and tertiary prevention strategies apply well to
bladder cancer. However, primary prevention implies that
the trade-oﬀ between the risk/inconvenience of intervention
and the anticipated beneﬁt is substantial because it pertains
to a nonaﬄicted population. It also implies that a population
at risk, in which intervention is warranted, can be iden-
tiﬁed. These restrictions make primary intervention, albeit
attractive conceptually, somewhat diﬃcult to implement in
practice. In contrast, tertiary intervention is already widely
practiced in bladder cancer in the form of intravesical
treatment, but other alternatives with lower toxicity have yet
to be fully explored.
7.1. Chemoprevention of Bladder Cancer by Nutritional Fac-
tors Green Tea and Catechins. Green tea and its derivatives
have been widely investigated as chemopreventive agents
for many cancers [157–159]. Epidemiological evidence sup-
ports an inverse relationship between increased green tea
consumption and bladder cancer risk [160]. The prevalence
of bladder cancer appears to be signiﬁcantly lower among
East Asian populations [6], which have much higher rates
of tea consumption than in western countries. Bushman10 Journal of Oncology
reported an approximately twofold increase in the risk of
bladder cancer among Japanese families two generations
after immigrating to the United States, thus implying
that environmental inﬂuences including reduced green tea
consumption could be contributing factors [161]. Green tea
extract contains polyphenols, which have strong antioxidant
properties. A transient elevation of the plasma antioxidant
activity has been demonstrated with green tea intake, but
no proven inhibition of carcinogenesis has yet been clearly
established [162].
Catechins (epicatechin, epicatechin-3-gallate, epigal-
locatechin, and epigallocatechin-3-gallate (EGCG)) are
thought to play a major role in the anticarcinogenic action
of polyphenolic mixtures. These agents inhibit nitrosamine
formation and decrease chromosomal damage [163]. Data
from several experimental in vitro and in vivo animal studies
support the anti-carcinogenic activity of green tea and its
derivatives in bladder cancer models. Kemberling et al. [164]
reported the inhibition of the growth of AY-27 rat urothelial
cancer cells by intravesical installation of the green tea
derivative EGCG. Sato and Matsushima [165] demonstrated
the prevention of N-butyl-N-(4-hydroxybutyl)-nitrosamine
(OH-BBN) experimentally induced urinary bladder tumors
by green tea leaves, when given before the administration
of the carcinogen. Polyphenols can also act as tumor
suppressors, blocking the enzyme ornithine decarboxylase
(ODC). This enzyme is expressed in bladder tumors, and
its action is regulated by EGF [166]. Further evidence comes
from a report by Lu et al. [167] demonstrating the promising
action of a green tea mixture modulating actin remodeling
through Rho activity in in vitro human bladder cancer
models generated using two nontransformed urothelial cell
lines, HUC-PC and MC-T11.
Green tea supplements were submitted for future investi-
gation and development as tumor preventive agents by the
National Cancer Institute [168]. A group of investigators
at the University of California, Los Angeles, has initiated
an NCI-funded Phase III multicenter clinical trial of green
tea supplements. This study is designed as a 3-arm trial
comparing green tea polyphenols with the epidermal growth
factor receptor antagonist, erlotinib, and placebo in former
smokerswithintermediateandhigh-risknonmuscleinvasive
bladder cancer in combination with maintenance bacille
Calmette-Gu´ erin (BCG). The study requires 110 patients in
each of the three arms, and it is currently being conducted at
UCLA and the Mayo Clinics in Scottsdale and Rochester.
7.1.1. Fruits and Vegetables. Epidemiological data regarding
fruits and vegetables as potential chemopreventive supple-
ments for bladder cancer have been inconsistent and con-
troversial. In 1997, an international review panel considered
vegetables as chemopreventive agents for bladder cancer
[169]. Increased detoxiﬁcation of urothelial carcinogens is
thought to be the mechanism underlying the protective
action of these supplements. In the prospective health
professionals follow-up study, an inverse but not statistically
signiﬁcant link between total fruit and vegetable intake and
the bladder cancer risk was seen [170] .Ah i g hc o n s u m p t i o n
of cruciferous vegetables has been shown to be associated
with a signiﬁcantly reduced risk of bladder cancer compared
to a low intake, especially in nonsmokers [170]. Another,
large prospective study from Japan concluded that in 39,000
survivors of an atomic bomb attack (15,000 males and
24,000 females), a 50% reduction in bladder cancer risk was
associated with high fruit and vegetable intake [171]. The
greater eﬀect was linked to the intake of green and yellow
vegetables. Overall, the regular consumption of vegetables
mighthaveastrongerprotectiveeﬀectagainstbladdercancer
than fruit intake, with a greater impact on the nonsmoking
population [172].
7.1.2. Soy Products. Increased intake of soy products has
been linked to reduced risk of breast, colon, and prostate
cancer [173, 174]. In a recent meta-analysis, Yan and
Spitznagel [175] reported an approximately 30% reduction
of prostate cancer risk associated with increased soy product
consumption. Soy products contain high concentrations of
several isoﬂavones. In vitro studies suggest that the protective
action of soy may derive in part from induction of G2-M
cell cycle arrest, apoptosis, and inhibition of angiogenesis
[176]. However, the relationship between soy consumption
andbladdercancerriskisstillunclear.Surprisingly,arecently
reported prospective cohort study of Chinese subjects from
Shanghai found a 2.18-fold increase in the risk of bladder
cancer associated with high ingestion of soy products after
adjustment for age, cigarette smoking, and level of education
[177]. This eﬀect was similar in smokers and non-smokers.
The conﬂicting role of soy products in the prevention of
prostate and bladder cancer magniﬁes the importance of
further investigation, before any deﬁnite recommendations
regarding these supplements as chemopreventive agents can
be made.
The isoﬂavone genistein, a natural soy product, has
receptor tyrosine kinase inhibiting activity, as well as phy-
toestrogenic and other purportedly anticarcinogenic eﬀects
[173, 178, 179]. This dietary agent is relatively nontoxic
when evaluated in human clinical trials. In in vitro systems,
genistein has been demonstrated to have antiurothelial
cancer activity. Growth inhibition of bladder cancer cells
in vitro has been associated with inhibition of cyclin B
expression, the development of a G2-M cell cycle arrest, and
induction of apoptosis [180]. The expression of the EGF-
R, whose quantity and distribution are associated with a
pan-urothelialabnormalities[181],increaseswithincreasing
tumorstageandaggressiveness[182].TheinhibitionofEGF-
R activity and EGF-mediated responses such as proliferation
and cell motility has been reported for genistein in bladder
cancer [183]. Additionally, in nonurothelial systems, the
expression and activity of cyclooxygenase (COX)-2, an
inducible enzyme whose upregulation has been associated
with transitional cell carcinogenesis, was downregulated by
genistein [184]. In addition, in other cell types critical for
tumor growth, such as endothelial cells, VEGF-mediated
inductionofcyclooxygenase(COX)-2wasinhibitedbygenis-
tein [185]. Importantly, many markers of these molecular
processes can be assessed by immunohistochemistry onJournal of Oncology 11
formalin ﬁxed, paraﬃn embedded tissues, and/or bladder
washes.While there is not any direct evidence demonstrating
genistein’s inhibition of EGF-R tyrosine phosphorylation in
bladder cancer, genistein is known to inhibit EGF/EGF-R-
mediated functions of human bladder cancer cells [183],
suchasproliferation,invasion,andmotility,anditisbelieved
that virtually all functions of the EGF-R are mediated by
signaling initiated by EGF-R tyrosine phosphorylation. It is
possible that in the case of the human bladder cancer EGF-R,
genistein’sinhibitoryeﬀectsareduemoretoalterationsofthe
downstream signaling pathways rather than EGF-R tyrosine
phosphorylation.
7.1.3. Selenium. The role of selenium as a chemopreventive
agent for bladder cancer also remains controversial. In the
Nurses Health Study with over 121,000 participants, 28 cases
of urinary tract cancer were detected [186]. No signiﬁcant
diﬀerence was observed in the selenium levels in toenail
clippings between cases and controls. Helzlsouer et al. [187]
analyzed various serum nutrients from 25,802 subjects in
Washington County, Md, USA. During the 12-year period,
35 cases of bladder cancer were identiﬁed. The level of
selenium was lower in individuals with bladder cancer
compared to two matched controls per case. Decreased
levels of selenium in the serum were associated with an
approximate linear increase in the risk of bladder cancer.
However, in a recent nested case-control study of 338 cases
and 341 matched controls, prediagnostic selenium levels in
archived toe nails were inversely linked with bladder cancer
risk in females (P for trend = 0.02), but not in males. Further
investigation is therefore needed to determine the true role
of selenium in the prevention of bladder cancer and whether
this role diﬀers by gender.
7.1.4. Garlic. Among the many purported actions of garlic,
inhibition of cancer growth is probably the most remarkable.
The growth inhibition of various tumor cell lines by
ingredients in dietary garlic, such as S-allylmercaptocysteine
has been reported [188]. Garlic may prevent the suppression
of the immune response and thus may decrease the risk
of malignancy [189]. Garlic has been evaluated in several
epidemiological studies for the prevention of prostate [190],
breast [191], colorectal [192], lung [193], and stomach
cancer [194] with conﬂicting results. Further clinical trials
are required to understand the true impact of garlic on the
reduction of cancer risk.
7.1.5. Fat Consumption. In a multicenter Spanish study, high
intake of saturated fat was associated with a greater than
two-fold increase in the incidence of bladder cancer [195].
In a meta-analysis of six dietary variables, Steinmaus et al.
[196] identiﬁed an association between a decreased bladder
cancer risk and lower dietary intake of fat. A hospital-
based case-control study assessed possible relationships
betweendiﬀerentdietarysupplementsandtheriskofbladder
cancer in Serbia [197]. The cohort was comprised of 130
newly diagnosed bladder cancer patients, and controls were
matched by sex, age, and other demographic variables. The
authors observed a potentially important role for dietary
fat in bladder carcinogenesis (OR = 2.99, 95% CI = 1.16–
7.72). There is additional evidence suggesting that this
carcinogenic action is dosedependent [198]. If conﬁrmed in
larger prospective trials in other populations, a low daily
dietary intake of fat could be recommended as one of the
possiblemeanstopreventthedevelopmentofbladdercancer.
7.1.6. Vitamins. Vitamin A, also known as retinol, exists
in natural and synthetic forms and can be derived from
carotenoids. An important role for vitamin A in the protec-
tion and support of epithelial integrity and cell diﬀerentia-
tion was established by several experimental studies [199].
Sporn et al. [200] reported inhibition of experimentally-
induced transitional and squamous cell bladder carcinomas
with 13-cis-retinoic acid. It was suggested that vitamin
A acts mainly through retinoic acid [201]. Signiﬁcantly
decreased serum levels of retinoids and carotene were found
in bladder cancer patients compared to controls in several
epidemiological studies [202]. The chemopreventive role
of vitamin A may be based on the antioxidant activity of
carotenoids via their reduction of DNA damage induced by
free radicals [203].
A high intake of retinoids can be toxic though and can
cause what is known as retinoid syndrome. The manifes-
tations of this syndrome include a steady fever, hypoten-
sion, respiratory dysfunction, conjunctivitis, cheilosis, and
arthralgia and can even be fatal. A study reported by the
National Bladder Cancer Collaborative Group comparing
the eﬀect of 13-cis-retinoic acid to placebo in patients
with rapidly recurring bladder cancer was terminated due
to excessive toxicity without any clear-cut beneﬁts in the
retinoid arm [204].
These potentially harmful eﬀects of vitamin A sup-
plements in some individuals (especially smokers) have
motivated investigators to develop synthetic retinoids and
retinamides with signiﬁcantly reduced systemic toxicity
and increased activity. Cliﬀord et al. [205]r e p o r t e dN-
4-hydroxyphenylretinamide (4-HPR or fenretinide) to be
an active inducer of bladder cancer cell apoptosis. In a
prospective, randomized, double-blind, multicenter trial.
Studer et al. [206] assessed the eﬀectiveness of etretinate in
preventing recurrence among patients who suﬀered from
superﬁcial bladder cancer. There were no diﬀerences in the
time to ﬁrst recurrence between those receiving etretinate
and those receiving placebo. However, the interval to second
recurrences was signiﬁcantly longer in the etretinate-treated
group (20 versus 12.7 months, resp., P = 0.006). This delayed
eﬀect of synthetic retinoids may reﬂect a cumulative drug
exposure eﬀect and support continuous treatment, within
the limits of acceptable toxicity. However, signiﬁcant cardiac
toxicity occurred in the etretinate arm in this study, and
further trials with this agent have not been performed.
Another multicenter phase III randomized chemopre-
vention trial compared fenretinide to placebo in patients
with TaG1 and G2 or patients with intermediate risk tumors
treated with BCG and also found no diﬀerence in the time to
ﬁrst recurrence between the two arms, suggesting no beneﬁt12 Journal of Oncology
for this synthetic vitamin A analog [207, 208]. Furthermore,
a 7-year prospective trial of 28,000 male smokers in Finland,
no protection against bladder cancer formation was seen
for β-carotene, alone or with a vitamin E analog. While
the ﬁndings of preclinical studies may have been promising,
to date, no consistent beneﬁt has been seen in the limited
clinical trial data available.
Vitamin B6 (pyridoxine) has also been studied as a
potential chemopreventive agent for bladder cancer. The
proposed mechanism of action of pyridoxine is based on its
ability to eliminate the carcinogenic action of some products
with an abnormal tryptophan metabolism (kynurenine, 3-
hydroxykynurenine, and 3-hydroxyanthranilic acid). These
metabolites were found in excessive concentrations in the
urine of bladder cancer patients [172]. In a Veterans Admin-
istration multicenter study reported by Byar and Blackard
[209], pyridoxine was signiﬁcantly more likely to prevent a
nonmuscle invasive bladder cancer than was a placebo, and
it was also as eﬀective as thiotepa. Conﬂicting results have
been observed in a double-blind randomized phase III study
c o n d u c t e db yt h eE O R T C[ 172]. A total of 291 patients with
non-muscle invasive bladder cancer were randomized 7–14
days after transurethral resection of newly diagnosed bladder
tumors to receive 20mg pyridoxine as a chemopreventive
agent or placebo. No diﬀerence in the rate or time to tumor
recurrence was found. Vitamin B6 may therefore have a mild
chemopreventive eﬀect against bladder cancer, but further
researchstudieswithalongerfollowupareneededtoprovide
deﬁnitive conclusions.
Vitamin C (ascorbic acid) is a potent water-soluble
antioxidant and acts as a free radical scavenger, reducing
the formation of bladder carcinogens such as 3-hydro-
xanthranilic acid and nitrosamines. Because of these prop-
erties, vitamin C can decrease chromosomal damage and
eliminate carcinogenic changes in the bladder urothelium
[210]. In several human studies, increased intake of vitamin
C supplements was associated with a reduction of bladder
cancer risk [211]. The health professionals follow-up study
found a strong inverse relationship between vitamin C intake
and bladder cancer risk in ex-smokers and non-smokers but
failed to show the same link with current smokers [212].
There may be a dose limit, beyond which vitamin C may act
as an inducer of carcinogenic activity, and high doses should
be avoided, especially in patients with a history of bladder
cancer [213]. Vitamin C supplements in doses beyond
the recommended dietary thresholds may also contribute
to hyperoxaluria and an increased risk of oxalate stone
formation in individuals predisposed to urinary calculi,
thereby potentially limiting its use as a chemopreventive
agent [214]. Moreover, the bladder cancer protective eﬀects
of vitamin C have not yet been prospectively assessed in
placebo-controlled trials.
Vitamin E is a lipid-soluble antioxidant that may act
as a chemopreventive agent in several ways. It is an active
free radical scavenger and reduces N-nitroso compounds
attenuating their carcinogenic eﬀect on the urothelium.
Additionally, vitamin E modulates the immune function and
induces apoptosis [215]. Several studies have reported an
inverse relationship between vitamin E intake and bladder
cancer risk [212]. The health professional follow-up study
showeda30%reductioninbladdercancerriskinex-ornon-
smokers when vitamin E supplements were consumed for
more than 10 years. This eﬀect was not found among current
smokers [212]. A large epidemiological study reported by
Jacobs et al. [216] found decreased bladder cancer mortality
in patients who used vitamin E supplements for 10 years
or more. However, in a Finish male smoker study that
included 28,000 subjects, no protection against bladder
cancer development was found with α-tocopherol either
alone or with the vitamin A analog, β-carotene [217].
Prospectivetrialsarerequiredinordertodeterminethelong-
termsafetyandroleofvitaminEasachemopreventiveagent.
It should be remembered that in high doses, vitamin E may
increase the bladder cancer risk, and overdoses can be fatal
[218, 219].
7.1.7. Lycopenes. Lycopenes are unsaturated, nonprovitamin
A carotenoids found in tomatoes, guava, rose hip, water-
melon, and pink grapefruit, giving these fruits their red
color. Lycopenes concentrate in speciﬁc compartments of
the body, including the breast, prostate, and pancreas. Like
other carotenoids, they are potent antioxidants and have
been suggested to reduce the risk of bladder cancer. A study
of the impact of a 12-week treatment with tomato juice in
rats initiated with a bladder carcinogen, OH-BBN, showed
a decrease in tumor number without aﬀecting the tumor
incidence [220].
7.1.8. Linoleic Acid. Linoleic acid is a polyunsaturated fatty
acid found in vegetable oils and meats. Both linoleic acid
and its stereoisomer, conjugated linoleic acid, which is
derived from ruminant animals and their dairy products,
have demonstrated an ability to suppress proliferation and
enhance apoptosis in bladder cancer cell lines [221, 222].
While linoleic acid exerted no eﬀects on the growth of cancer
cells, conjugated linoleic acid inhibited the growth in a dose-
dependent manner [221]. Although these recent in vitro data
are encouraging, in vivo studies are necessary before linoleic
acidandconjugatedlinoleicacidcanbeadvocatedtoprevent
bladder cancer development.
7.1.9. Other Nonnutritional Agents. Based on the ﬁndings
that antioxidative substances modulate bladder carcinogene-
sis in rodents [223], our group reported several natural com-
pounds that eﬀectively suppressed experimental bladder car-
cinogenesisinratsandmice.Theyincludeastaxanthin[224],
protocatechuic acid [225], diosmin [226], hesperidin [226],
silymarin [227], 1,4-phenylene diisothiocyanate [228], and
β-cryptoxanthin [229] .T h e s ec o m p o u n d sa r er e a d yt ob e
evaluated for eﬃcacy in clinical trials.
7.2. Chemoprevention of Bladder Cancer by Synthetic Chemi-
cals (Drugs) Diﬂuoromethylornithine (DFMO). In the induc-
tion of the synthesis of polyamines through the activation of
the enzyme, ODC has been reported to be closely associated
with tumor promotion and the activities of both hormones
and growth-promoting factors [73]. Increased ODC activityJournal of Oncology 13
has been found in a variety of cancers, including urothelial
cancer [73], and its activity can be blocked by using a
noncompetitive inhibitor, DFMO. DFMO has been found to
selectively inhibit the growth of malignant human urothelial
cells in vitro compared to normal cells. This eﬀect can be
reversed by supplementing the medium with the polyamines
putrescine or spermidine, important in DNA synthesis and
gene expression [73], indicating that its primary inhibit-
ing eﬀect is likely mediated through polyamine depletion.
DFMO also inhibits the development of carcinogen-induced
urothelial cancer in rodents and other models [73, 230]. This
agenthasbeentestedinelderlypatients(includingthosewith
bladder cancer) in oral doses that are well tolerated [231]
and that reduce ODC activities in malignant urothelial tissue
[232].
A study by Messing et al. [233] was undertaken to
determine if DFMO could prevent recurrences of completely
resected low-risk bladder cancer compared with placebo and
to determine the incidence and severity of adverse events
associated with receiving DFMO for up to 1 year in this
patient population. A randomized, double blind, placebo-
controlled trial was conducted in patients with grade 1 or
2, stage Ta or TI, newly diagnosed or occasionally recurrent
(less than one recurrence per year and no more than three
total recurrences) urothelial cancers. Within 12 weeks of
complete endoscopic resection, patients were randomized
and started to receive 1g of oral DFMO or placebo once
per day, with treatment to be continued for 12 months or
until histologically conﬁrmed tumor recurrence, whichever
wassooner.Inthelargestbladdercancerpreventiontrialever
conducted, 454 patients were randomized at 70 clinical sites
in the United States, Canada, and the United Kingdom. A
total of 194 patients (90 DFMO and 104 placebo) completed
the 12-month treatment period, while 248 (130 DFMO, 118
placebo)discontinuedtreatmentearly.Toxicitywaslow,with
adverse events noted in 6.6% of patients receiving DFMO
and 5.7% on placebo. However, DFMO did not reduce
the frequency of recurrence or delay the time to ﬁrst or
subsequent recurrences in the population as a whole, nor in
any stratiﬁcation category. Forty-four percent of recurrences
in the DFMO arm and 51% in the placebo arm occurred
within 6 months of randomization, and another 29% in the
DFMO arm and 28% in the placebo arm occurred within the
next 6 months. Over 73% of ﬁrst recurrences in both groups
occurred within the ﬁrst year of the study.
7.2.1. Nonsteroidal Anti-Inﬂammatory Drugs (NSAIDs) and
Selective COX-2 Inhibitors. NSAIDs are one of the most
potent bladder cancer chemopreventive agents in preclinical
studies [234]. This class of drugs blocks the expression of
COX, the key enzyme in prostaglandin synthesis. COX exists
in two predominant isoforms, COX-1 and COX-2. COX-1 is
ubiquitouslyexpressedandconstitutivelyactiveinthegastric
mucosa, kidneys, and platelets (among other cell types).
InhibitionofCOX-1bynonselectiveNSAIDsleadstoplatelet
dysfunction, gastritis, and occasional renal dysfunction, and
therefore these agents are not always well tolerated during
chronic administration. In a large prospective study of
aspirin users, no relationship was found between aspirin
intake and urothelial cancer risk [235] .H o w e v e r ,ar e c e n t
case-controlled study from California demonstrated a 20%
decrease in bladder cancer risk among the population with
regular use of NSAIDs [236]. The chemopreventive eﬀect
of NSAIDs is thought to result from COX-2 inhibition.
COX-2 is inducible by inﬂammatory cytokines, hormones,
growth factors and tumor promoters. Prostaglandin E2
(PGE2) is the end product of eicosanoid synthesis which is
mediated by COX-1 and COX-2. PGE2 can stimulate cell
proliferation and motility while inhibiting apoptosis and
immune surveillance. Similarly, PGE2 can stimulate tumor-
driven angiogenesis. Inhibition of COX-2 may block these
and other procarcinogenic properties, thus contributing
to the chemopreventive activities of this class of selective
NSAIDs [237].
Data from preclinical in vivo studies supports the link
between the up-regulation of COX-2 and the occurrence
of bladder cancer [238]. The tumor suppressive eﬀect of
celecoxib, a selective COX-2 inhibitor, is thought to be dose-
dependent, and stronger at higher doses [239]. Gee et al.
[240] evaluated the chemopreventive and therapeutic prop-
erties of the selective COX-2 inhibitors, celecoxib, and NS-
398, on three diﬀerent human bladder cancer cell lines (UM-
UC-1, 3, and 6). Celecoxib induced signiﬁcant apoptosis
in all three cell lines, acting through the downregulation
of Bcl-2. Both NS-398 and celecoxib demonstrated dose-
dependent tumor cell growth inhibition modulated by a
signiﬁcant reduction in the number of cells in the S-phase
[240]. The growth inhibitory activity of these selective COX-
2 inhibitors was independent of the COX-2 expression levels,
thus suggesting the presence of additional anticarcinogenic
eﬀects, other than inhibition of COX-2.
In human bladder tissue, COX-2 is expressed in urothe-
lial dysplasia, Tis, and in the majority of TCCs, indepen-
dent of stage and grade [241, 242]. Shariat et al. [243]
described the patterns of COX-2 expression in patients with
carcinoma in situ and/or stage T1 TCC and reported an
association of >10% immunoreactivity with the progression
of Tis but not T1 disease, and no association with overall
survival. These clinical ﬁndings suggest that selective COX-
2 inhibitors are an appropriate class of drugs to evaluate
in human clinical prevention trials because they have a
higher tolerability proﬁle than nonselective NSAIDs, which
predominantly block COX-1 [156, 231]. A multicenter study
led by MD Anderson Cancer Center and supported by the
NationalCancerInstituteandPﬁzerIncorporatedtoevaluate
a selective COX-2 inhibitor in patients with nonmuscle
invasive bladder cancer treated with BCG is ongoing [244].
Patients who showed a complete response to an induction
course of 6 instillations of BCG and completed at least
one 3-week maintenance course of BCG were eligible for
randomization to 1 or 2 years of 200mg twice per day of
celecoxib or a placebo. The primary endpoint of the study is
the time to recurrence after 12 months of treatment with the
studydrug.Thestudydesigncalledfor156evaluablepatients
in each arm with a power of 80% to detect a 41% reduction
in recurrence. Secondary aims include assessment of the
modulation of several biomarkers, including prostaglandin14 Journal of Oncology
dehydrogenase (PGDH), basic ﬁbroblast growth factor, the
autocrine motility factor receptor, and markers of prolifera-
tion and apoptosis. Modulation of these biomarkers will be
examined for a correlation with tumor recurrence. Accrual
has been completed, but not all patients have completed the
treatment protocol, and the results are thus pending.
It should be remembered that long-term exposure to
COX-2 inhibitors has the potential to be harmful and has
been associated with a well-publicized small, but signiﬁcant,
elevation in cardiovascular (CV) events [245]. There has
been no signiﬁcant CV toxicity in a celecoxib Trial, but
several selective NSAIDs have been taken oﬀ the market, and
the ability to test this class of agents in future bladder cancer
prevention trials may be limited. This is particularly true
for primary prevention, which is performed in subjects who
have never had bladder cancer and are not considered to be
at as high of a risk as those who have already had tumors.
7.2.2. Statins. A class of hydroxymethylglutaryl-coenzyme
A reductase inhibitors, the statins, has been suggested to
decrease the risk of multiple cancers, including bladder
cancer and prostate cancer. The mechanism(s) responsible
for this eﬀect is unclear although cholesterol is considered
to be one of the mediators of tumorigenesis. It is therefore
logical that drugs that decrease lipoproteins, such as the
statins, can decrease cancer growth and tumor progression
[246]. In vivo studies of statins are necessary before clinical
trials are planned.
7.2.3. Antibiotics. Oltipraz, an antiparasitic agent (5-[2-
pyrazinyl]-4-methyl-1,2-3-thione), originally developed as
anantischistosomalmedication,wasfoundtoprotectagainst
chemically induced carcinogens in the lung, stomach, colon,
and urinary bladder in animals. The mechanisms of oltipraz
actionincludeenhancementofDNArepairprocesses,induc-
tion of phase I enzymes (cytochrome P450) that enhance
carcinogen detoxiﬁcation, and nucleophilic trapping of
reactive intermediates, among others. Oltipraz inhibits the
carcinogenesis induced by polycyclic aromatic hydrocarbons
and N-nitrosamine agents that constitute some of the
carcinogenic components of tobacco. Recent reports have
indicated that oltipraz may have anticarcinogenic activity as
well.
The antiangiogenic and antitumor eﬃcacy of oltipraz
in nude mice was evaluated by measuring its eﬀects on
neovascularization in subcutaneous implants seeded with
vascular endothelial growth factor and basic ﬁbroblast
growth factor-stimulated porcine aortic endothelial cells,
and on tumor growth and angiogenesis in SVR murine
angiosarcoma xenografts implanted subcutaneously [247].
A dose-dependent reduction (0.4–100μM) in microvessel
genesis was observed in bioassays after oltipraz treatment,
with decrease of 100% in the rat aortic ring assay at the
highest concentration (P < 0.01). Administration of the
oltipraz to athymic mice bearing established subcutaneous
SVR angiosarcoma xenografts for 10 days resulted in a
signiﬁcant inhibition of tumor growth as early as day 4 after
the beginning of treatment (P < 0.005), with a maximum
inhibition of tumor growth (81%, P < 0.001) relative to
vehicle-treated mice by day 10.
The eﬃcacy of oltipraz approached the angiogenesis
inhibiting eﬀects of known anti-angiogenic agents, such as
SU 5416 (semaxanib). Phase I trials conducted in the United
States have shown that the maximum tolerated dose of
oltipraz is approximately 125mg/day, over a 6-month period
[248]. Dose-limiting toxicities included photosensitivity,
heat intolerance, gastrointestinal toxicities, and neurologic
toxicities [249, 250]. Oltipraz is unique in its multiple
mechanisms of action as an antischistosomal, antiangiogenic
and anticarcinogenic agent. Its chemopreventive eﬀects
should therefore be beneﬁcial for patients with a history of
Schistosoma haematobium bladder infections who are known
to be at an increased risk for developing bladder cancer as
well as in smokers. This agent may also be eﬀective in the
treatment of advanced stage cancers. However, oltipraz has
not yet been studied in phase III chemopreventive trials.
8. Animal Models of Bladder Cancer
Appropriate and valid animal models for urinary bladder
carcinogenesis must be similar to human bladder can-
cer in their histology, biochemical properties, molecular
and genetic characteristics, natural history, and biological
behavior [251]. A simple and natural method for the
administration of the carcinogen is required; the carcinogen
ought to be nontoxic and should ideally aﬀect only the
urothelium.
Three chemicals have proven to be particularly eﬀective
to induce bladder neoplasms. These chemicals include N-
[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT), OH-
BBN, and N-methyl-N-nitrosourea (MNU) [252]. These
compounds are complete carcinogens, and the total dose
has a greater eﬀect when administered as several fractions,
that is, the eﬀect of the fractions is synergistic rather than
additive. The grade of cellular atypia and the extent of
invasion increase as the dose of carcinogen increases, as well
as when the experimental period is extended [253]. A fried
food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline,
also results in bladder cancer [254]. Among them, OH-
BBN is the most suitable urinary bladder carcinogen for
animal models, since its carcinogenic potential is essentially
limited to this organ, and it is probably the most commonly-
referenced experimental bladder carcinogen [255]. Bladder
tumors induced by OH-BBN in rats and mice resemble
their human counterparts [256]. OH-BBN is a metabolite
of the symmetric dibutylnitrosamine (DBN) [257]. In rats,
both were demonstrated to be urinary bladder carcinogens,
with OH-BBN being speciﬁc to the urinary bladder, because
DBN also induced tumors of the liver, lung, kidney and
esophagus [258]. Similar ﬁndings have been shown in
mice [259]. OH-BBN is bladder speciﬁc not only in rats,
but also in mice and dogs. A 100% incidence of bladder
tumors can be induced in rats and mice by continuous
and prolonged administration of OH-BBN in drinking
water. The animal bladder carcinogenesis model using OH-
BBN, thus, is useful for investigating bladder carcinogenesis,Journal of Oncology 15
screening cancer chemopreventive agents, and determining
therapeutic eﬃcacy of new anticancer agents.
Multistage models of carcinogenesis proposed to explain
the patterns of tumor development observed in the urinary
bladder involve the initiation of neoplastic changes in a
few cells by a threshold dose of carcinogen, followed by
conversion of these latent tumor cells into an autonomous
cancer by further doses of the same and/other carcino-
gens, and/or promoting agents. In the urinary bladder of
mice and rats, neoplastic changes can be initiated by a
few weeks of treatment with low doses of the chemical
carcinogens described above. Animals subsequently exposed
to promoter compounds, such as sodium and potassium
salts, urolithiasis-inducing agents, and certain antioxidants,
develop increased number of bladder cancer [213, 260].
9. Conclusion
We now have a good understanding of the pathobiology of
bladder cancer development from the large body of evidence
provided by experimental and epidemiological studies. In
addition, numerous experimental and epidemiological stud-
ies have shown a promising response of bladder cancer to
several potential chemopreventive agents. However, limited
clinical data in well-designed prospective trials for the
prevention of bladder cancer have been less encouraging.
Future large randomized clinical trials are needed before
deﬁnite recommendations can be established regarding
eﬀorts to reduce bladder cancer recurrence rates, and to
improve overall outcomes. The clinical challenges related to
preventing and treating bladder cancer will increase as our
population ages and chemoprevention shows promise in this
battle, because of the recurrent nature of bladder cancer.
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